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The Royal College of Surgeons (RCS) guide to surgical prioritisation during the coronavirus pandemic 
states that breast reconstruction is Priority level 4 Surgery. In view of the associated increased 
mortality risk, and potential complications such as return to theatre, autologous free tissue transfer for 
breast reconstruction was withheld in our unit from the 12th March.   
It is the view in our regional centre that free tissue transfer for breast reconstruction should not be 
viewed as complex surgery.   We believe in performing the correct operation, for the right patient, at 
the right time and we strive to adhere to the NHS improvement program 'Getting it right first time'.  
After widespread consultation with stakeholders both locally and nationally, as of June 3rd we re-
started autologous free flap reconstruction.  We describe our experience as the first unit in 


















The Royal College of Surgeons (RCS) guide to surgical prioritisation during the coronavirus (COVID-
19) pandemic states that breast reconstruction is Priority level 4 Surgery, meaning it can be 
delayed for over three months
1
.  The 30-day mortality in elective surgery patients diagnosed peri-
operatively with COVID-19 may be as high as 19.1%
2
.  In view of the associated mortality risk, and 
potential complications such as return to theatre, autologous free tissue transfer for breast 
reconstruction was withheld in our unit from the 12th March.   
It is the view in our regional centre that free tissue transfer for breast reconstruction should not be 
viewed as complex surgery.   We believe in performing the correct operation, for the right patient, at 
the right time and we strive to adhere to the NHS improvement program GIRFT (getting it right first 
time).  
After widespread consultation with stakeholders both locally and nationally, as of June 3rd we re-
started autologous free flap reconstruction.  We describe our experience as the first unit in 
resuming this service during the COVID-19 pandemic. 
 
Stage 1- Discussion stage with key stakeholders 
 
With limited resources and time available, it was important to prioritise patients and maintain 
discussion of reconstruction on a trust director level agenda. Cases were discussed on an individual 
basis using the RCS prioritisation as a guideline. Categories of patients that we felt would require 
reconstruction during Phase 1 were reviewed regularly and highlighted to surgical directors.  Our 
exclusion criteria were adapted according to both the emerging situation within our unit and in the 
medical literature.  
 
Stage 2-  Development of pathway  
 
We developed an evidence based pathway that selected low risk patients and then minimised their 
potential pre-operative and inpatient COVID-19 exposure.  The commitment and approval of our 
nursing and physiotherapist colleagues has been central to the service re-opening.   Multidisciplinary 
ownership of the pathway was key to engaging the senior management team.  Furthermore, the 
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nursing staff provided data on the practical availability of trained theatre and ward staff.  The 
enthusiasm of a large group of motivated individuals created momentum to restart the 
service.  Theatre lists were reduced and pooled.  
 
Low risk patients attend a pre-operative virtual forum consultation with surgeons, specialist nurses 
and physiotherapists.  This is where most information is provided, in order to reduce the length of the 
subsequent face-to-face consultation.  
 
Prioritisation of cases on a Divisional Operations level was based on clinical needs as well as 
requirement and availability of resources.  We expected four hours of operating and did not plan to 
take breaks or change scrub nurse intraoperatively, thereby reducing personal protective equipment 
usage.  Two plastic surgery consultants were supported by an experienced scrub team.  We 
presented this streamlined theatre plan to theatre managers.  This was particularly important as 
during Phase 2 the theatre workforce was reduced by 30%.   
Our enhanced recovery protocol includes patient discharge on day two.  Our pathway for restarting 
DIEPs was presented to the hospital executive board. Whilst the trust directors were considering the 
proposal, potential low risk surgical candidates were identified. 
 
Stage 3- National consensus and support from colleagues 
 
On May 15th, our unit chaired an online meeting to gauge the national viewpoint on breast 
reconstruction and initiate discussion. This concluded 72% (22/30) plastic surgeons were ready to 
resume reconstruction within three months. There was particular concern regarding the 
growing waiting list for delayed DIEPs, safety of surgery and implications for training. There was also 
recognition of the national variation of COVID-19 effects on hospitals.  Our unit had 40% inpatient 
capacity.    Through this meeting we gained support from key stakeholders such as BAPRAS which 
was essential to resuming our reconstruction service.  
  
Stage 4- Safety and consent  
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In line with the Montgomery ruling
3
,  all forms of reconstruction and associated additional COVID-19 
risks were discussed with patients. Our exclusion criteria, shown in Table 1, is based on current best 
evidence, and our own experience of a DIEP patient with COVID-19
2,4
. Our initial protocol criteria 
utilises age, comorbidity and body mass index, although we expect to move to using the clinical frailty 
score as our experience grows. 
Our legal team was consulted to discuss how risks of exposure and complications were presented 
and provided us with patient information leaflets. As a result, we have a dedicated section in our 
reconstruction virtual forum discussing the risks of COVID-19. We have also devised a procedure-
specific consent form for our DIEPs which includes a section on COVID-19 risks and complications. 
 
Stage 5- Service Recommenced  
We recommenced operating on June 3rd. Initially we booked low-risk patients whom were accepting 
of the additional hazard of COVID-19.  
 
A powerful tool for resuming reconstruction was the reconstruction forum to discuss cases for 
immediate autologous reconstruction this allowed categorisation to level 2.  We are closely monitoring 
our service, and depending on the future epidemiology of COVID-19, we will continue to adapt our 
pathway. 
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Table 1. Exclusion criteria 
Age > 60 years 
All smokers and recent ex-smokers (< 2 years) 
Patients with a cancer history other than the breast cancer 
Pre-operative lymphopenia count 
Pre-operative low vitamin D 
Cardiovascular disease (AF and previous MI/ stroke/TIA) 
Hb < 10 
Patients who live in a household with 1) high risk individuals 2) key workers whom are unable to 
isolate 
Patients unable to accept 72-hour hospital stay 
BMI > 30 
Bilateral (for June) 
Poor perforators on CT angiogram 
Active respiratory disease 
We select low risk patients at a virtual reconstruction MDT jointly lead by breast and plastic surgeons. 
Any attendance to the hospital is mapped on a ‘green route’ whereby patients are able to enter and 
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pass through our pre-screened, lowest risk ward.  AF, Atrial fibrillation; MI, Myocardial infarction; TIA, 
Thromboembolic event; Hb, Heamoglobin; BMI, Body mass index; CT, Computerised tomography 
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